Produkty 98665-20-4

CAS 98665-20-4 występuje w naszej ofercie pod nazwami: Ganoderic acid I, Ganoderic acid I, Ganoderic acid I, ≥98%, ≥98%, Ganoderic acid I, 99.14%. Oferty producentów: GLPBio, Biosynth, Chemat, MedChemExpress. Dostępne opakowania: 1mg, 5mg, 10mg, 25mg, 10 mg, 5 mg.

Ganoderic acid I
GLPBio
  • opakowanie: 1mg, 5mg
  • Warianty: 2
od 1111,89
Zobacz produkt
Ganoderic acid I
Biosynth
  • opakowanie: 10mg, 25mg
  • Warianty: 2
Zobacz produkt
Ganoderic acid I, ≥98%, ≥98%
Chemat
  • opakowanie: 5mg, 10mg
  • Warianty: 2
od 2061,20
Zobacz produkt
Ganoderic acid I, 99.14%
MedChemExpress
  • opakowanie: 10 mg, 5 mg
  • Warianty: 2
od 2135,50
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(2R,6S)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-4-oxoheptanoic acid (CAS 98665-20-4) to związek chemiczny o wzorze sumarycznym C30H44O8 i masie molowej 532.7 g/mol. Nazwa systematyczna IUPAC: (2R,6S)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-4-oxoheptanoic acid. InChIKey: ZWMMEKXOLCCKLA-OCYWOBKISA-N.

Dane identyfikacyjne
Wzór sumarycznyC30H44O8
Masa molowa532.7 g/mol
Nazwa IUPAC(2R,6S)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-4-oxoheptanoic acid
InChIKeyZWMMEKXOLCCKLA-OCYWOBKISA-N
SMILESC[C@H](CC(=O)C[C@@](C)([C@@H]1CC(=O)[C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)C)O)C(=O)O

Dane obliczone przez PubChem (NCBI)

Synonimy: Ganoderic acid I, orb3179974, (25R)-3beta,7beta,20-Trihydroxy-11,15,23-trioxo-17alpha-lanost-8-en-26-oic acid, (3I(2),7I(2),25R)-3,7,20-Trihydroxy-11,15,23-trioxolanost-8-en-26-oic acid
Izomery (ten sam wzór sumaryczny)
(1R,2R,4R,5R,6S,7S,9R,10S,11S,13S,14R,15R,25R)-10,11-dihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-prop-1-en-2-yl-8,24,26,27-tetraoxaheptacyclo[12.10.1.14,23.15,23.01,6.07,9.011,25]heptacosan-12-one C30H44O8
3-[6-(3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl)oxy-9,13-dimethyl-17-oxo-14-tetracyclo[11.3.1.01,10.04,9]heptadecanyl]-2H-furan-5-one C30H44O8
(6R)-2-methyl-4-oxo-6-[(3S,5R,7S,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid C30H44O8
2-methyl-4-oxo-6-(3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid C30H44O8
[(2S,3R,4S)-2-[(3R,4aR,6aR,12S,12aS,12bR)-12-hydroxy-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate C30H44O8
(E,4S,6R)-4-hydroxy-2-methyl-6-[(3S,5R,7S,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid C30H44O8
3-[(1S,3R,6R,7R,10R,11S,14S,16R)-14-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-7,11-dimethyl-2-oxapentacyclo[8.8.0.01,3.03,7.011,16]octadecan-6-yl]-2H-furan-5-one C30H44O8
(2S,8S,9R,10R,13R,14S,16R,17R)-17-[(E,2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,16-dihydroxy-9-(hydroxymethyl)-4,4,13,14-tetramethyl-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,11-dione C30H44O8
(2R,6R)-6-[(4R,5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4-(hydroxymethyl)-4,10,13,14-tetramethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid C30H44O8
(6R)-6-[(5R,7S,10S,13R,14R,15S,17S)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-4-oxoheptanoic acid C30H44O8
[(2S,3R,4S)-2-[(3R,4aR,6aS,12S,12aS,12bR)-12-hydroxy-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate C30H44O8